AAA
INZY

Affinity Asset Advisors’s Inozyme Pharma INZY Stock Holding History

Affinity Asset Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,749,359
Closed -$7M – 107
2025
Q2 		$7M Sell
1,749,359
-2,118,351
-55% -$5.25M 0.96% 32
2025
Q1 		$3.52M Sell
3,867,710
-104,608
-3% -$145K 0.34% 53
2024
Q4 		$11M Buy
3,972,318
+1,150,000
+41% +$4.37M 1.47% 23
2024
Q3 		$14.8M Sell
2,822,318
-33,934
-1% -$176K 2.01% 16
2024
Q2 		$12.7M Buy
2,856,252
+213,733
+8% +$1.04M 1.47% 20
2024
Q1 		$20.2M Buy
2,642,519
+756,717
+40% +$4.15M 2.51% 12
2023
Q4 		$8.03M Buy
1,885,802
+505,950
+37% +$1.8M 1.47% 22
2023
Q3 		$5.8M Buy
1,379,852
+628,056
+84% +$3.19M 1.63% 22
2023
Q2 		$4.19M Hold
751,796
– – 1.46% 23
2023
Q1 		$4.31M Buy
751,796
+251,796
+50% +$665K 1.42% 23
2022
Q4 		$525K Buy
+500,000
New +$874K 0.21% 57

Affinity Asset Advisors's INZY Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 1,749,359 shares — an estimated $7M sold.

Affinity Asset Advisors first reported a position in INZY in Q4 2022 and held it in 11 quarters. The position peaked at $20.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • Affinity Asset Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 1,749,359 Inozyme Pharma shares in Q3 2025, an estimated $7M.
  • Affinity Asset Advisors first reported a position in Inozyme Pharma in Q4 2022 and held it in 11 quarters.
  • Affinity Asset Advisors's Inozyme Pharma position peaked at $20.2M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.